Sponsors (3)
The bill accelerates and expands commercialization support for SBIR/STTR awardees — improving access to funding, IP protection, training, and market‑oriented review — at the cost of greater administrative and reporting burdens, potential shifts away from basic research, and short‑term funding reallocations that create uncertainty and equity concerns.
Small businesses and research teams gain substantially expanded commercialization support and funding flexibility (new flexible awards, designated commercialization officials, ability to use award funds for assistance/hiring, and more agency coordination) that make it easier to transition technologies to market.
Small businesses and inventors receive faster access to critical commercialization milestones — quicker SBIR/STTR decision timelines and prioritized USPTO examination — which speeds funding flow and earlier IP protection.
Award selection will more often reflect market potential because peer reviews must include a commercialization assessment and at least one reviewer with commercialization expertise, improving chances that commercially viable projects receive support.
Researchers and institutions focused on basic or early‑stage science may be disadvantaged because increased emphasis on near‑term commercialization shifts selection and program focus away from high‑value long‑term research.
Eligible small businesses face substantial reporting, compliance, and confidentiality burdens — including multi‑year firm‑level financial data — increasing administrative cost, proprietary-data risk, and the time required to participate.
Federal agencies and the SBA will incur additional administrative workload and personnel costs (designating commercialization officials, administering I‑Corps options, reporting, coordinating with USPTO) that may be unfunded and divert resources from program delivery.
Based on analysis of 8 sections of legislative text.
Prioritizes commercialization in SBIR/STTR reviews, creates agency Technology Commercialization Officials, expands allowable assistance and I‑Corps participation, sets assistance caps, adds reporting and a USPTO patent assistance partnership.
Introduced May 7, 2025 by Christina Houlahan · Last progress May 7, 2025
Shortens SBIR/STTR review timelines and adds a stronger commercialization focus to peer review, requires each participating agency to designate a Technology Commercialization Official to help move awardees toward market entry, and expands allowable use of award funds for technical and business assistance (including I‑Corps participation). It also creates limits on use of expanded Phase funding, requires new commercialization reporting and a standardized annual commercialization impact assessment, and directs the SBA to partner with the USPTO to provide patent assistance for award recipients. The bill changes how agencies evaluate and support small business research projects by prioritizing commercialization, setting per-project assistance caps ($6,500 Phase I, $50,000 Phase II), broadening which agencies may use expanded phase flexibility (with agency caps), and adding new reporting and interagency coordination requirements to improve transitions from research to market.